Gain Therapeutics (GANX) Short Interest Ratio & Short Volume → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free GANX Stock Alerts $2.10 -0.10 (-4.55%) (As of 02:58 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Gain Therapeutics Short Interest DataCurrent Short Interest100,700 sharesPrevious Short Interest154,200 sharesChange Vs. Previous Month-34.70%Dollar Volume Sold Short$263,834.00Short Interest Ratio0.9 Days to CoverLast Record DateMay 15, 2024Outstanding Shares18,050,000 sharesFloat Size16,690,000 sharesShort Percent of Float0.60%Today's Trading Volume195,501 sharesAverage Trading Volume147,545 sharesToday's Volume Vs. Average133% Short Selling Gain Therapeutics ? Sign up to receive the latest short interest report for Gain Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGANX Short Interest Over TimeGANX Days to Cover Over TimeGANX Percentage of Float Shorted Over Time Ad Smallcaps DailyIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution Gain Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024100,700 shares $263,834.00 -34.7%0.6%0.9 $2.62 4/30/2024154,200 shares $451,806.00 +3.1%1.0%1 $2.93 4/15/2024149,600 shares $462,264.00 +8.3%1.1%0.9 $3.09 3/31/2024138,100 shares $520,637.00 -11.9%1.0%0.9 $3.77 3/15/2024156,700 shares $672,243.00 +16.4%0.9%0.9 $4.29 2/29/2024134,600 shares $604,354.00 -2.2%0.8%0.8 $4.49 Get the Latest News and Ratings for GANX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024137,600 shares $660,480.00 +13.4%0.8%0.9 $4.80 1/31/2024121,300 shares $469,431.00 +17.2%0.7%0.8 $3.87 1/15/2024103,500 shares $361,215.00 +66.1%0.6%1.2 $3.49 12/31/202362,300 shares $203,409.50 -42.0%0.4%0.7 $3.27 12/15/2023107,400 shares $268,500.00 -25.0%0.6%1.6 $2.50 11/30/2023143,200 shares $306,448.00 -18.9%1.2%2.4 $2.14 11/15/2023176,500 shares $511,850.00 -3.2%1.7%3.8 $2.90 10/31/2023182,400 shares $521,664.00 -9.5%1.8%4.9 $2.86 10/15/2023201,600 shares $665,280.00 +6.4%2.0%4.8 $3.30 9/30/2023189,500 shares $621,560.00 +5.2%1.9%4.5 $3.28 9/15/2023180,100 shares $666,370.00 +14.1%1.8%5.5 $3.70 8/31/2023157,900 shares $522,649.00 -6.4%1.6%4.5 $3.31 8/15/2023168,600 shares $606,960.00 +61.5%1.7%4.3 $3.60 7/31/2023104,400 shares $414,468.00 +66.0%1.1%2.3 $3.97 7/15/202362,900 shares $279,276.00 -6.5%0.7%0.9 $4.44 6/30/202367,300 shares $301,504.00 +21.7%0.7%1 $4.48 6/15/202355,300 shares $269,311.00 +24.8%0.6%0.8 $4.87 5/31/202344,300 shares $204,223.00 -19.6%0.5%0.5 $4.61 5/15/202355,100 shares $279,908.00 -7.9%0.6%0.7 $5.08 4/30/202359,800 shares $300,794.00 -7.1%0.7%0.8 $5.03 4/15/202364,400 shares $308,476.00 +7.3%0.7%0.9 $4.79 3/31/202360,000 shares $289,200.00 +20.2%0.7%1.1 $4.82 3/15/202349,900 shares $220,558.00 +64.1%0.6%0.9 $4.42 2/28/202330,400 shares $126,464.00 +35.7%0.3%0.7 $4.16 2/15/202322,400 shares $87,360.00 -16.7%0.3%0.5 $3.90 1/31/202326,900 shares $106,255.00 +45.4%0.3%0.7 $3.95 1/15/202318,500 shares $71,783.70 -70.5%0.2%0.5 $3.88 12/30/202262,700 shares $196,251.00 -10.7%0.6%1.9 $3.13 12/15/202270,200 shares $210,600.00 +146.3%0.7%2.3 $3.00 11/30/202228,500 shares $86,640.00 -25.4%0.3%1 $3.04 11/15/202238,200 shares $119,184.00 -21.1%0.4%1.2 $3.12 10/31/202248,400 shares $161,656.00 +6.6%0.5%1.4 $3.34 10/15/202245,400 shares $143,010.00 -30.3%0.5%1.2 $3.15 9/30/202265,100 shares $212,226.00 +50.0%0.8%1.5 $3.26It's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution 9/15/202243,400 shares $169,260.00 +80.8%0.6%1 $3.90 8/31/202224,000 shares $82,800.00 -35.0%0.3%0.5 $3.45 8/15/202236,900 shares $153,135.00 -27.8%0.5%0.7 $4.15 7/31/202251,100 shares $203,378.00 +29.4%0.7%0.7 $3.98 7/15/202239,500 shares $158,395.00 -17.9%0.5%0.5 $4.01 6/30/202248,100 shares $173,160.00 -30.9%0.6%0.3 $3.60 6/15/202269,600 shares $224,808.00 +18.2%0.9%0.4 $3.23 5/31/202258,900 shares $175,522.00 -24.6%0.8%0.4 $2.98 5/15/202278,100 shares $208,527.00 +125.1%1.0%0.5 $2.67 4/30/202234,700 shares $118,674.00 -4.9%0.5%0.2 $3.42 4/15/202236,500 shares $140,160.00 No Change0.5%0.3 $3.84 3/31/202236,500 shares $149,285.00 +18.5%0.5%0.6 $4.09 3/15/202230,800 shares $103,180.00 -17.9%0.4%0.6 $3.35 2/28/202237,500 shares $138,375.00 -42.0%0.5%0.7 $3.69 2/15/202264,700 shares $270,446.00 +100.3%0.8%1.1 $4.18 1/31/202232,300 shares $129,200.00 -8.0%0.4%0.4 $4.00 1/15/202235,100 shares $164,268.00 +30.0%0.5%0.4 $4.68 12/31/202127,000 shares $146,610.00 -25.4%0.4%0.4 $5.43 12/15/202136,200 shares $204,530.00 -14.6%0.5%0.5 $5.65 11/30/202142,400 shares $306,976.00 +74.5%0.6%0.5 $7.24 11/15/202124,300 shares $208,008.00 +35.0%0.3%0.1 $8.56 10/29/202118,000 shares $125,280.00 -23.7%0.2%0.1 $6.96 10/15/202123,600 shares $163,784.00 -5.2%0.3%0.2 $6.94 9/30/202124,900 shares $185,505.00 -63.5%0.3%0.2 $7.45 9/15/202168,200 shares $543,554.00 +170.6%0.9%0.5 $7.97 8/31/202125,200 shares $196,560.00 -42.1%0.3%0.2 $7.80 8/13/202143,500 shares $348,000.00 No Change0.6%1.6 $8.00 GANX Short Interest - Frequently Asked Questions What is Gain Therapeutics' current short interest? Short interest is the volume of Gain Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 100,700 shares of GANX short. 0.60% of Gain Therapeutics' shares are currently sold short. Learn More on Gain Therapeutics' current short interest. What is a good short interest ratio for Gain Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GANX shares currently have a short interest ratio of 1.0. Learn More on Gain Therapeutics's short interest ratio. What is a good short interest percentage for Gain Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.60% of Gain Therapeutics' floating shares are currently sold short. Is Gain Therapeutics' short interest increasing or decreasing? Gain Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 100,700 shares, a decline of 34.7% from the previous total of 154,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Gain Therapeutics' float size? Gain Therapeutics currently has issued a total of 18,050,000 shares. Some of Gain Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gain Therapeutics currently has a public float of 16,690,000 shares. How does Gain Therapeutics' short interest compare to its competitors? 0.60% of Gain Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Gain Therapeutics: Evogene Ltd. (0.15%), Passage Bio, Inc. (3.92%), Hookipa Pharma Inc (1.11%), X4 Pharmaceuticals, Inc. (7.27%), Trevi Therapeutics, Inc. (1.40%), Capricor Therapeutics Inc (13.23%), Abeona Therapeutics Inc (7.76%), Incannex Healthcare Inc. (0.39%), Lifecore Biomedical, Inc. (6.86%), Organigram Holdings Inc. (5.84%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Gain Therapeutics stock? Short selling GANX is an investing strategy that aims to generate trading profit from Gain Therapeutics as its price is falling. GANX shares are trading down $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Gain Therapeutics? A short squeeze for Gain Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GANX, which in turn drives the price of the stock up even further. How often is Gain Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GANX, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: EVGN Short Squeeze PASG Short Squeeze HOOK Short Squeeze XFOR Short Squeeze TRVI Short Squeeze CAPR Short Squeeze ABEO Short Squeeze IXHL Short Squeeze LFCR Short Squeeze OGI Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GANX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.